Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Status and phase: Enrolling; Phase 1

Conditions: Solid Tumor; Hepatocellular Carcinoma; Lung Cancer

Treatments: Combination Product: CpG-ODN

Study type: Interventional

Funder types: Other

Identifiers

NCT04952272

ZZITCpG-013

Details and patient eligibility

About

To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.

Full description

1. Percutaneous microwave ablation or intratumor injection of drug-eluting beads to destroy cancer cells to release tumor-specific antigens
2. Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40
3. Assessing side effects and therapeutic efficacy after the combined treatments

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Solid advanced malignant tumors
• Age between18 and 80 years
• Life expectancy is greater than three months

Exclusion criteria

• Benign tumor
• Life expectancy is less than three months
• Serious medical comorbidity
• Others

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Intratumor CpG-ODN Injection

Experimental group

Description:

CpG-ODN will be Injected into the tumor.

Treatment:

Combination Product: CpG-ODN